Abstracts tagged "longitudinal studies"

Abstract Number: 2053 • 2014 ACR/ARHP Annual Meeting
Mortality Decreases in Patients with Rheumatoid Arthritis: a 15-Year Prospective Cohort Study
Joëlle van den Hoek^1,2, Hendriek C. Boshuizen³, Leo D. Roorda⁴, Gerard J. Tijhuis⁵, Mike T. Nurmohamed⁵, Trudi van den Bos² and Joost Dekker^6,7, ¹Rehabilitation Research Center, Reade, Rehabilitation | Rheumatology, Amsterdam, Netherlands, ²Social Medicine, Academic Medical Center, Amsterdam, Netherlands, ³National Institute of Public Health and the Environment, Bilthoven, Netherlands, ⁴Amsterdam Rehabilitation Research Center | Reade, Amsterdam, the Netherlands, Amsterdam, Netherlands, ⁵Rheumatology, Jan van Breemen Research Institute | Reade, Amsterdam, Netherlands, ⁶Rehabilitation Medicine, Psychiatry and EMGO Institute for Health and Care Research, VU University Medical Center, Amsterdam, Netherlands, ⁷Reade, centre for Rehabilitation and Rheumatology, Amsterdam, Netherlands
Background/Purpose Patients with rheumatoid arthritis (RA) have a higher mortality risk than the general population, with similar patterns over the last decades. However, more recent…
Abstract Number: 2054 • 2014 ACR/ARHP Annual Meeting
Physical and Mental Functioning in Patients with Established Rheumatoid Arthritis over an 11-Year Follow-up Period: The Role of Specific Comorbidities
Joëlle van den Hoek¹, Leo D. Roorda², Hendriek C. Boshuizen³, Gerard J. Tijhuis⁴, Trudi van den Bos⁵ and Joost Dekker⁶, ¹Rehabilitation Research Center, Reade, Rehabilitation | Rheumatology, Amsterdam, Netherlands, ²Amsterdam Rehabilitation Research Center | Reade, Amsterdam, the Netherlands, Amsterdam, Netherlands, ³National Institute of Public Health and the Environment, Bilthoven, Netherlands, ⁴Rheumatology, Jan van Breemen Research Institute | Reade, Amsterdam, Netherlands, ⁵Social Medicine, Academic Medical Center, Amsterdam, Netherlands, ⁶Rehabilitation Medicine, Psychiatry and EMGO Institute for Health and Care Research, VU University Medical Center, Amsterdam, Netherlands
Background/Purpose Comorbidity in patients with Rheumatoid Arthritis (RA) is highly prevalent and plays an important role in determining RA related outcomes. Several studies have reported…
Abstract Number: 2047 • 2014 ACR/ARHP Annual Meeting
No Association of Serum Uric Acid with Hip Fracture Risk in Older Men and Women from the Framingham Original Cohort
Shivani Sahni¹, Kelsey Mangano², Katherine Tucker³, Caroline Fox⁴, Douglas P. Kiel⁵, Xiaochun Zhang⁶ and Marian T. Hannan¹, ¹Institute for Aging Research, Hebrew SeniorLife, Dept. of Medicine Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, ²Musculoskeletal Research, Institute for Aging Research, Hebrew SeniorLife, Dept. of Medicine Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, ³Clinical Laboratory & Nutritional Sciences, Center for Population Health & Health Disparities, University of Massachusetts, Lowell, MA, ⁴Institute of Genetics and Biophysics, NHLBI's Framingham Heart Study and Center for Population Studies, Framingham, MA, ⁵Institute for Aging Research, Hebrew SeniorLife, Dept. of Medicine Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, ⁶Musculoskeletal Research, Institute for Aging Research, Hebrew SeniorLife, Roslindale, MA
Background/Purpose: Serum uric acid (UA) has been linked with fractures in older men. Three different studies in older men showed conflicting results. The objective…
Abstract Number: 1286 • 2014 ACR/ARHP Annual Meeting
The Natural Course of Physical Function in People with Symptomatic Knee Osteoarthritis: Data from the Osteoarthritis Initiative
Britt Elin Øiestad¹, Daniel White², Ross Booton³, Jingbo Niu³, Yuqing Zhang⁴, James C. Torner⁵, Cora E. Lewis⁶, Michael C. Nevitt⁷, Michael P. Lavalley⁸ and David T. Felson⁹, ¹Department of Orthopedics, Oslo University Hospital, 0407 Oslo, Norway, ²Clinical Epidemiology Training, Boston Univ School of Med, Boston, MA, ³Clinical Epidemiology Research and Training Unit, Boston University, Boston, MA, ⁴Boston University School of Medicine, Boston, MA, ⁵Epidemiology, University of Iowa, Iowa City, Iowa City, IA, ⁶Preventive Medicine, The University of Alabama at Birmingham, Birmingham, AL, ⁷Epidemiology & Biostatistics, UCSF (University of California, San Francisco), San Francisco, CA, ⁸Biostatistics, Boston University, Boston, MA, ⁹Clinical Epidemiology Research & Training Unit, Boston University School of Medicine, Boston, MA
Background/Purpose: Longitudinal studies of people with knee osteoarthritis (OA) have reported stable or improved physical function, contrary to the progressive degenerative nature of OA. The…
Abstract Number: 1062 • 2014 ACR/ARHP Annual Meeting
Impact of Obesity on 1 Year Outcomes: Results from the Meteor Foundation International Rheumatoid Arthritis Cohort
Christopher Sparks¹, Robert Moots¹, Eftychia Psarelli², Tom Huizinga³ and Nicola Goodson¹, ¹Musculoskeletal Biology1, University of Liverpool, Liverpool, United Kingdom, ²Cancer Research UK Liverpool Cancer Trials Unit, University of Liverpool, Liverpool, United Kingdom, ³Rheumatology, Leiden University Medical Center, Leiden, Netherlands
Background/Purpose Increased adiposity is associated with increased production of pro-inflammatory adipokines and raised inflammatory markers. As a result, standard disease activity scores (DAS) may be…
Abstract Number: 907 • 2014 ACR/ARHP Annual Meeting
Ultrasonographic Tenosynovitis Score Is Responsive to Biologic Treatment in Patients with Rheumatoid Arthritis
Hilde B. Hammer¹ and Tore K. Kvien², ¹Dept of Rheumatology, Diakonhjemmet Hospital, Oslo, Norway, ²Dept. of Rheumatology, Diakonhjemmet Hospital, Oslo, Norway

Background/Purpose: Ultrasound (US) is sensitive for detecting tenosynovitis in patients with rheumatoid arthritis (RA), where the synovitis can be assessed by grey scale (GS) and…
Abstract Number: 849 • 2014 ACR/ARHP Annual Meeting
Tofacitinib, an Oral Janus Kinase Inhibitor, in the Treatment of Rheumatoid Arthritis: Safety and Efficacy in Open-Label, Long-Term Extension up to 6 Years
J. Wollenhaupt¹, J. Silverfield², E.B. Lee³, S.P. Wood⁴, K. Terry⁴, H. Nakamura⁵, K. Kwok⁶, A. Anisfeld⁶, C. Nduaka⁴, R. Riese⁴ and L. Wang⁴, ¹Schoen-Klinik Hamburg-Eilbek Teaching Hospital of the University of Hamburg, Hamburg, Germany, ²Healthpoint Medical Group, Tampa, FL, ³Seoul National University, Seoul, South Korea, ⁴Pfizer Inc, Groton, CT, ⁵Pfizer Inc, Tokyo, Japan, ⁶Pfizer Inc, New York, NY
Background/Purpose: Tofacitinib is an oral Janus kinase inhibitor for the treatment of rheumatoid arthritis (RA). Here we report tofacitinib safety, tolerability, and durability of response…
Abstract Number: 392 • 2013 ACR/ARHP Annual Meeting
Prevalence Of Cardiovascular Risk Factors and Cardiovascular Disease In Rheumatoid Arthritis Patients Across International Regions: A Comparison Of The Corrona International and Corrona United States Registries
Dimitrios A. Pappas¹, Kathy Lampl², Joel M. Kremer³, Sebastião C. Radominski⁴, Janos Gal⁵, Fredrik Nyberg⁶, Anand N. Malaviya⁷, Aimée Whitworth⁸, Oscar Luis Rillo⁹, Allan Gibofsky¹⁰, Tatiana Popkova¹¹, Meilien Ho¹², Ieda Laurindo¹³, George W. Reed⁸, Eduardo Mario Kerzberg¹⁴, Laura Horne¹⁵, Roman Záhora¹⁶, Katherine C. Saunders¹⁷, Bernado Pons-Estel¹⁸, Alina U. Onofrei¹⁹ and Jeffrey D. Greenberg²⁰, ¹Columbia University, New York, NY, ²AstraZeneca R&D Wilmington, Wilmington, DE, ³Center for Rheumatology, Albany Medical College, Albany, NY, ⁴Universidade Federal do Paraná, Curitiba, Brazil, ⁵Rheumatology, County Hospital, Kecskemet, Hungary, ⁶AstraZeneca R&D, Mölndal, Sweden, ⁷Rheumatology, Consultant Rheumatologist, ISIC Superspeciality Hospital, New Delhi-11007-, India, ⁸CORRONA, Inc., Southborough, MA, ⁹Hospital Tornú, Capital Federal, Argentina, ¹⁰Medicine and Public Health, Hospital for Special Surgery, New York, NY, ¹¹Research Institute of Rheumatology -Russian Academy of Medical Science, Moscow, Russia, ¹²AstraZeneca R&D Alderley Park, Macclesfield, United Kingdom, ¹³Rheumatology, Universidade de São Paulo, São Paulo, Brazil, ¹⁴Rheumatology, J. M. Ramos Mejía Hospital, School of Medicine, University of Buenos Aires, Buenos Aires, Argentina, ¹⁵AstraZeneca, Wilmington, DE, ¹⁶Revmatologická ambulance, Terezin, Czech Republic, ¹⁷Corrona, LLC., Southborough, MA, ¹⁸Hospital Provincial de Rosario, Rosario, Argentina, ¹⁹University of Massachusetts Medical School, Worcester, MA, ²⁰Rheumatology, NYU Hospital for Joint Diseases, New York, NY
Background/Purpose: Cardiovascular disease (CVD) is a major comorbidity in patients (pts) with rheumatoid arthritis (RA). We explored variations in the prevalence of cardiovascular (CV) risk…
Abstract Number: 290 • 2013 ACR/ARHP Annual Meeting
Children With JIA Show Distinct Patterns Of Improvement In Their Health-Related Quality Of Life During The First Year On Treatment: Growth Mixture Modeling Of a Prospective Cohort Of Newly Diagnosed Patients
Bin Huang¹, Chen Chen², Stacey Niehaus³, Hermine Brunner⁴, Rina Mina⁵ and Michael Seid⁶, ¹Biostatistics and Epidemiology, Cincinnati Children's Hospital Medical Center/University of Cincinnati School of Medicine, Cincinnati, OH, ²Biostatistics and Epidemiology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ³Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ⁴Cincinnati Children's Hospital Medical Center/University of Cincinnati School of Medicine, Cincinnati, OH, ⁵Rheumatology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ⁶Pulmonary, Cincinnati Children's Hospital Medical Center/University of Cincinnati School of Medicine, Cincinnati, OH
Background/Purpose: Health-related quality of life (HRQOL) is a key outcome in clinical care and research for children with JIA. Despite excellent clinical control and the…
Abstract Number: 251 • 2013 ACR/ARHP Annual Meeting
Physical Activity Is Associated With Reduced Incident Disability: Evidence From The Osteoarthritis Initiative
Dorothy D. Dunlop¹, Jing Song¹, Pamela A. Semanik², Leena Sharma², Joan M. Bathon³, Charles Eaton⁴, Marc C. Hochberg⁵, Rebecca D. Jackson⁶, C. Kent Kwoh⁷, W, Jerry Mysiw⁶, Michael C. Nevitt⁸ and Rowland W. Chang¹, ¹Northwestern University Feinberg School of Medicine, Chicago, IL, ²Northwestern University, Chicago, IL, ³Columbia University, New York, NY, ⁴Center for Primary Care and Prevention, Memorial Hospital of Rhode Island, Providence, RI, ⁵Medicine, University of Maryland School of Medicine, Baltimore, MD, ⁶Ohio State University, Columbus, OH, ⁷School of Medicine, Department of Medicine, Division of Rheumatology and Clinical Immunology, University of Pittsburgh, Pittsburgh, PA, ⁸Epidemiology & Biostatistics, UCSF (University of California, San Francisco), San Francisco, CA
Background/Purpose: Over 56 million people in the U.S. are classified as disabled. Physical activity is a low cost, broadly applicable approach to improve cardiovascular fitness,…
Abstract Number: 2763 • 2013 ACR/ARHP Annual Meeting
Carotid Atherosclerosis As a Predictor Of Mortality In Rheumatoid Arthritis
Inmaculada del Rincon¹, Roy W. Haas², Jose Felix Restrepo³, Daniel F. Battafarano⁴, Daniel H. O'Leary⁵, Emily Molina¹ and Agustin Escalante⁶, ¹Rheumatology, University of Texas Health Science Center, San Antonio, TX, ²Dept. of Medicine-Rheumatology, University of Texas Health Science Center, San Antonio, TX, ³Rheumatology, University of Texas Health Science Center at San Antonio, San Antonio, TX, ⁴Medicine / MCHE-MDR, Brooke Army Medical Ctr, San Antonio, TX, ⁵Radiology, Tufts University-Boston Campus, Boston, MA, ⁶Dept. of Medicine-Rheumatology, University of Texas Health Science Center at San Antonio, San Antonio, TX
Background/Purpose: Patients with rheumatoid arthritis (RA) have higher mortality than do persons of the same age and sex without RA. This is due in part…
Abstract Number: 2752 • 2013 ACR/ARHP Annual Meeting
Good, Moderate and Poor Outcome Trajectories Of Pain Severity In Early Symptomatic Knee Osteoarthritis; 5 Year Follow-Up Of Check study
Janet Wesseling¹, Alex N. Bastick², Sita M.A. Bierma-Zeinstra³ and Johannes W.J. Bijlsma⁴, ¹Rheumatology & Clinical Immunology, University Medical Center Utrecht, Utrecht, Netherlands, ²General Practice, Erasmus MC - University Medical Center, Rotterdam, Netherlands, ³Orthopaedics and General Practice, Erasmus MC - University Medical Center, Rotterdam, Netherlands, ⁴Department of Rheumatology and Clinical Immunology, University Medical Center Utrecht, Utrecht, Netherlands
Background/Purpose: Knee pain is often the first sign of knee OA (osteoarthritis) and it is known that its course can be very different between patients over…
Abstract Number: 2328 • 2013 ACR/ARHP Annual Meeting
Tofacitinib, An Oral Janus Kinase Inhibitor, In The Treatment Of Rheumatoid Arthritis: Open-Label, Long-Term Extension Safety and Efficacy Up To 5 Years
Jürgen Wollenhaupt¹, Joel Silverfield², Eun Bong Lee³, Susan P. Wood⁴, Ketti K. Terry⁴, Hiroyuki Nakamura⁵, Yukako Ohno⁵, David Gruben⁴, Birgitta Benda⁶, Lisy Wang⁴ and Richard Riese⁴, ¹Schoen-Klinik Hamburg-Eilbek Teaching Hospital of the University of Hamburg, Hamburg, Germany, ²Healthpoint Medical Group, Tampa, FL, ³Seoul National University, Seoul, South Korea, ⁴Pfizer Inc, Groton, CT, ⁵Pfizer Japan Inc, Tokyo, Japan, ⁶Pfizer Inc, Collegeville, PA
Background/Purpose: Tofacitinib is a novel, oral JAK inhibitor for the treatment of rheumatoid arthritis (RA). Here we report tofacitinib safety, tolerability, and durability of response…
Abstract Number: 1942 • 2013 ACR/ARHP Annual Meeting
Ultrasound Shows Tenosynovitis to be Frequently Present as Well As Sensitive to Change in RA Patients On Biologic Medication
Hilde B. Hammer, Dept of Rheumatology, Diakonhjemmet Hospital, Oslo, Norway
Background/Purpose: Ultrasound (US) (grey scale (GS) and power Doppler (PD)) is a sensitive tool for examination of tenosynovitis in patients with rheumatoid arthritis (RA). The…
Abstract Number: 1430 • 2013 ACR/ARHP Annual Meeting
Safety and Efficacy Of Subcutaneous Tocilizumab Monotherapy In a Long-Term Extension Study In Japanese Rheumatoid Arthritis Patients
Atsushi Ogata, Respiratory Medicine, Allergy and Rheumatic Diseases, Osaka University Graduate School of Medicine, Suita, Japan
Background/Purpose: Tocilizumab (TCZ) blocks interleukin-6-receptor signaling and is an effective rheumatoid arthritis (RA) therapy. The MUSASHI1 and SUMMACTA2 studies showed the efficacy and safety of…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].